CDISC Therapeutic Area Data Standards: User Guide for Breast Cancer (Version 1.0 Provisional) Page 2 © 2016 Clinical Data Interchange Standards Consortium, Inc. All rights reserved May 16, 2016 Provisional CONTENTS 1 INTRODUCTION ................................................................................................................. 4 1.1 PURPOSE ................................ ................................ ................................ ................................ ................................ 4 1.2 ORGANIZATION O F THIS DOCUMENT ................................ ................................ ................................ ..................... 5 1.3 CONCEPT MAPS ................................ ................................ ................................ ................................ ..................... 5 1.4 CONTROLLED TERMINOLOGY ................................ ................................ ................................ ................................ 6 1.5 RELATIONSHIPS TO OTHER STANDARDS ................................ ................................ ................................ ................ 6 1.6 KNOWN ISSUES ................................ ................................ ................................ ................................ ...................... 7 2 OVERVIEW OF BREAST C ANCER ................................................................................. 8 3 SUBJECT AND DISEASE CHARACTERISTICS .......................................................... 10 3.1 DIAGNOSIS ................................ ................................ ................................ ................................ .......................... 10 3.2 STAGING ................................ ................................ ................................ ................................ .............................. 12 3.3 PATHOLOGY ................................ ................................ ................................ ................................ ........................ 13 3.3.1 Examples for Pathology ................................ ................................ ................................ ....................... 20 3.4 PRIOR TREATMENTS ................................ ................................ ................................ ................................ ............ 22 3.4.1 Examples for Prior Treatments ................................ ................................ ................................ ............. 22 3.5 RISK FACTORS ................................ ................................ ................................ ................................ ..................... 25 4 DISEASE MANAGEMENT A ND ASSESSMENTS ....................................................... 26 4.1 TREATMENTS ................................ ................................ ................................ ................................ ....................... 27 4.1.1 Examples for Treatments ................................ ................................ ................................ ...................... 28 4.1.2 Treatment Side Effects ................................ ................................ ................................ ......................... 29 4.2 TUMOR IDENTIFICATION , ASSESSMENT , AND DISEASE RESPONSE ................................ ................................ ....... 30 4.2.1 Examples for Tumor Identification and Assessment ................................ ................................ ............ 30 4.3 DISEASE RECURRENCE ................................ ................................ ................................ ................................ ........ 40 4.3.1 Examples for Disease Recurrence ................................ ................................ ................................ ........ 42 5 ANALYSIS DATA ............................................................................................................... 44 5.1 ANALYSIS ENDPOINTS ................................ ................................ ................................ ................................ ......... 45 5.1.1 Time to Event ................................ ................................ ................................ ................................ ....... 45 5.1.1.1 Progression- free Survival – (PFS) ................................ ................................ ................................ ........ 45 5.1.1.2 Overall Survival – (OS) ................................ ................................ ................................ ........................ 48 5.1.1.3 Event -free Survival – (EFS) ................................ ................................ ................................ ................. 49 5.1.1.4 Disease- free Survival – (DFS) ................................ ................................ ................................ .............. 49 5.1.1.5 Duration of Response – (DOR) ................................ ................................ ................................ ............ 50 5.1.2 Response Endpoints ................................ ................................ ................................ ............................. 50 5.1.2.1 Best Overall Response – (BOR) ................................ ................................ ................................ ........... 50 5.2 TABLE SHELLS ................................ ................................ ................................ ................................ .................... 51 5.3 ANALYSIS DATASETS ................................ ................................ ................................ ................................ .......... 52 5.3.1 Subject -Level ................................ ................................ ................................ ................................ ....... 52 5.3.2 Intermediate Event Dataset ................................ ................................ ................................ ................... 53 5.3.2.1 Use of a Provisional Variable ................................ ................................ ................................ ............... 54 5.3.3 Efficacy Analysis Datasets ................................ ................................ ................................ ................... 56 APPENDICES ............................................................................................................................. 59 APPENDIX A: PROJECT PROPOSAL ................................ ................................ ................................ ................................ 59 APPENDIX B: CFAST BRCA TEAM ................................ ................................ ................................ .............................. 60 APPENDIX C: GLOSSARY AND ABBREVIATIONS ................................ ................................ ................................ ........... 61 APPENDIX D: NON-STANDARD VARIABLES ................................ ................................ ................................ ................. 63 APPENDIX E: CLINICAL BACKGROUND ................................ ................................ ................................ ......................... 64